Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000981820
Ethics application status
Approved
Date submitted
7/09/2012
Date registered
12/09/2012
Date last updated
12/09/2012
Type of registration
Prospectively registered

Titles & IDs
Public title
A trial to assess which method of delivering local anaesthetic in to the abdominal wall provides the best pain relief after major gynaecological cancer surgery.
Scientific title
A double blinded randomised controlled trial assessing and comparing the total average 24 to 48 hour post surgical morphine usage and analgesic quality of 3 types of abdominal wall block catheters (transversus abdominis plane versus rectus sheath plane versus subcutaneous plane) in participants receiving midline laparotomy for gynaecological oncology surgery.
Secondary ID [1] 281186 0
NIL
Universal Trial Number (UTN)
U1111-1134-4069
Trial acronym
CAAB trial (Continuous Anterior Abdominal Wall Block)
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Postoperative pain 287362 0
Gynaecological cancer 287381 0
Condition category
Condition code
Anaesthesiology 287692 287692 0 0
Anaesthetics
Cancer 287713 287713 0 0
Ovarian and primary peritoneal
Cancer 287714 287714 0 0
Womb (Uterine or endometrial cancer)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants are randomised to receive either a catheter inserted in to transversus abdominis plane, rectus sheath plane or subcutaneous plane. All procedures will be performed at the end of the operation whilst under general anaesthesia by one of the investigators. During surgery participants will receive prophylactic antiemetics (Metoclopramide 20mg and Tropisetron 2mg intravenously) and a single dose of Parecoxib 40mg intravenously (unless contraindicated). All groups for a duration og 48 hours post surgery will receive 18ml boluses of 0.5% ropivacaine every 4 hours via a Y catheter (9 mls each side) at a total of 540 mg/day . The participants will be studied for 48 hours and the catheter will remain in situ for this time. The catheters will be removed on the third post operative day (48-72 hours post surgery). In addition for the first 48 hours post surgery patients will receive pain relief in the form of a morphine PCA and regular paracetamol. Intravenous antiemetics will be administered as required.
Intervention code [1] 285646 0
Treatment: Other
Intervention code [2] 285668 0
Treatment: Devices
Comparator / control treatment
The morphine consumption will be compared in the three catheter groups. It is hypothesised that the subcutaneous catheter group will provide the least effective analgesia and thus is our control group
Control group
Active

Outcomes
Primary outcome [1] 287941 0
To compare the total average 24 to 48 hour post surgical morphine usage between the three groups (transverse abdominis plane (TAP) catheter group, posterior rectus sheath (PRS) catheter group and subcutaneous catheter group).
Timepoint [1] 287941 0
measured at 24 and 48 hours post surgery
Secondary outcome [1] 299085 0
VAS pain scores at rest and movement
Timepoint [1] 299085 0
24 and 48 hours post surgery
Secondary outcome [2] 299086 0
Peak flow measurements (hand held peak flow meter, best of three)
Timepoint [2] 299086 0
24 and 48 hours
Secondary outcome [3] 299087 0
Nausea and vomiting scores (VAS - 0-10cm line)
Timepoint [3] 299087 0
24 and 48 hours
Secondary outcome [4] 299088 0
average sedation scores (0-3 nurse assessed)
Timepoint [4] 299088 0
0-24 and 24-48 hours post surgery
Secondary outcome [5] 299089 0
Patient satisfaction scores : 3 question VAS scale (How would you rate your satisfaction with the pain relief? If you needed another operation will you request the same analgesia again? Would you recommend this type of analgesia to a friend?)
Timepoint [5] 299089 0
at 24 and 48 hours

Eligibility
Key inclusion criteria
Women who are undergoing a laparotomy for gynaecological oncology procedures with an expected midline incision.
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Conditions associated with opioid tolerance: regular opioid analgesia use in the last three months, previous IVDU
Abdominal wall block technically difficult to perform: eg obesity (BMI > 35)
Contraindication to abdominal wall block: local sepsis, local anaesthetic allergy, abnormal anatomy (for example nephrectomy scars)
Preference for other technique for postoperative analgesia, such as epidural infusion.
Presence of stoma
Age less than 18.
Inadequate capacity to consent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Recruitment and consent
All patients of the Mater Adult Public Hospital undergoing midline laparotomy for gynaecological oncology procedures will be eligible.
Patients will be given an information sheet when booked for surgery by the gynaecological oncologist. They will have the opportunity to discuss the trial with an anaesthetist at an anaesthetic assessment clinic and written consent will be obtained if possible.
Patients will then be approached on the day of surgery in the admissions area (or their room) by the investigator. They will be reassessed for the inclusion and exclusion criteria and, once consent has been obtained, the baseline data will be collected.
If suitable for the study, information about the study will be reiterated: study purpose; design; benefits; and risks. Informed consent will be obtained if not yet done so.
Study participants will verify that they have read and understood the information sheet and verify that they have had any questions about the study answered and then read and sign the consent form
Once consent is obtained, the treating anaesthetist will be notified of the patient's enrolment. If the treating anaesthetist is an investigator, another investigator will seek consent from the patient.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation
Computer random allocation software will be used to generate a simple random sequence table prior to the start of the trial using three groups and a sample size of 90.
The randomisations will be concealed in 90 sealed envelopes labelled participant 1 to 90.
After obtaining written consent and commencement of anaesthesia (immediately after a midline incision has been performed), an envelope will be opened revealing the participant’s allocated group (A,B or C : A=Subcutaneous infusion catheter, B=TAP infusion catheter or C=Posterior rectus sheath catheter).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Participants are randomised to receive one of 3 interventions (transversus abdominis/rectus sheath/subutaneous catheters) after their abdominal surgery. After 90 participants have completed the trial each group will be statistically analysed and compared.
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/10/2012
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
90
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 285961 0
Hospital
Name [1] 285961 0
Mater Anaesthetic research fund
Country [1] 285961 0
Australia
Primary sponsor type
Hospital
Name
Mater Health Services
Address
Mater Health Services
Raymond Terrace
South Brisbane
QLD 4101
Country
Australia
Secondary sponsor category [1] 284785 0
None
Name [1] 284785 0
Address [1] 284785 0
Country [1] 284785 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 287995 0
Mater Health Services Human Research Ethics Committee
Ethics committee address [1] 287995 0
Ethics committee country [1] 287995 0
Australia
Date submitted for ethics approval [1] 287995 0
Approval date [1] 287995 0
21/08/2012
Ethics approval number [1] 287995 0
Ref No. 1912AM

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34683 0
Address 34683 0
Country 34683 0
Phone 34683 0
Fax 34683 0
Email 34683 0
Contact person for public queries
Name 17930 0
Phillip Cowlishaw
Address 17930 0
Mater Health Services
Raymond Terrace
South Brisbane
QLD 4101
Country 17930 0
Australia
Phone 17930 0
+61 7 31638646
Fax 17930 0
Email 17930 0
phillip.cowlishaw@mater.org.au
Contact person for scientific queries
Name 8858 0
Phillip Cowlishaw
Address 8858 0
Mater Health Services
Raymond Terrace
South Brisbane
QLD 4101
Country 8858 0
Australia
Phone 8858 0
+61 7 31638646
Fax 8858 0
Email 8858 0
phillip.cowlishaw@mater.org.au

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.